CAS NO: | 93616-27-4 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
Cas No. | 93616-27-4 |
别名 | 替考拉宁A3-1,Antibiotic L 17054 |
化学名 | 34-O-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-22,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy-42-O-α-D-mannopyranosyl-ristomycin A aglycone |
Canonical SMILES | C/C(O)=N/[C@]([C@@](O[C@]([C@@]1([H])/C(O)=N/[C@@](C(O)=O)([H])C(C=C(O)C=C2O[C@]3([H])[C@](O)([H])[C@](O)([H])[C@@](O)([H])[C@@](O3)([H])CO)=C2C4=C(O)C=CC([C@](/N=C(O)/[C@@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C5=CC6=C(O)C=C5)([H])CC7=CC(Cl)=C |
分子式 | C72H68Cl2N8O28 |
分子量 | 1564.3 |
溶解度 | Soluble in ethanol;Soluble in methanol;Soluble in DMSO;Soluble in dimethyl formamide |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Teicoplanin A3-1, also known as Antibiotic L 17054, is a glycopeptide antibiotic derived from Actinoplanes teichomyceticus and produces a potent broad spectrum antibiotic activity against gram-positive bacteria. Teicoplanin A3-1 is a common degradation product of teicoplanins A2-1 to 5, which results from cleavage of the lipoaminoglycoside substituents. Teicoplanins are glycopeptide antibiotics produced by A. teichomyceticus which are effective against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and E. faecalis. As an antibiotic complex, teicoplanin consists of five closely related factors, T-A2-1, 2, 3, 4 and 5 and a more polar factor, T-A3-1. Additionally, as a glycopeptide antibiotic belonging to the same family as vancomycin, teicoplanin blocks cell wall synthesis in Bacillus subtilis, which is accompanied by an intracellular accumulation of UDP-N-acetylmuramyl-pentapetide [1]. Due to the greater antibacterial activity of teicoplanin than other agents, it has been thoroughly studied as a β-1actamase-resistant agent for the treatment of human infections caused by streptococci and staphylococci, including enterococci [2]. In vitro: Up to now, in vitro study of Teicoplanin A3-1 is still in the development stage. In vivo: Up to now, in vivo study of Teicoplanin A3-1 is still in the development stage. References: |